Passaro A, Wang J, Shah S, Bauml JM, et al. Letter to the Editor regarding 'Correspondence to: Amivantamab plus chemotherapy with and without lazertinib in EGFR-mutant advanced NSCLC after disease progression on osimertinib: primary results from the phase III MARIPOSA-2 study' by Moik F, Riedl Ann Oncol 2024;35:328-329.
PMID: 38029840